Advanced HR+/HER2- Breast Cancer Clinical Trials

6 clinical trials for Advanced HR+/HER2- Breast Cancer across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors — RECRUITING · PHASE1
• Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer — RECRUITING · PHASE1
• Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors — WITHDRAWN · PHASE1
• Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED — COMPLETED · PHASE2

Refine this search